Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + zimberelimab + chemotherapy versus nivolumab + chemotherapy in first-line advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma
2022-002222-27Phase 3Active
- Sponsor
- Arcus Biosciences
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Domvanalimab + zimberelimab + chemotherapy with Nivolumab + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Sep 2022; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2022-002222-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002222-27.